|
Fig. 10 Effect of EN on AKT/GSK-3β/β-catenin pathway at the present of AKT inhibitor A-443654 in hMSCs. (a) Protein levels of AKT/GSK-3β/β-catenin pathway in hMSCs were detected by western blotting on day 14: (b) β-catenin/GAPDH, p-GSK-3β (ser9)/GSK-3β, p-AKT/AKT. The data are shown as the means ± SD (n = 3). ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 vs. OIM; ◇◇◇P < 0.001 vs. A-443654; ◆◆P < 0.01, ◆◆◆P < 0.001 vs. EN. EN, eurycomanone (p-) AKT (phosphorylated-) protein kinase B (p-) GSK-3β (ser9) (phosphorylated-) glycogen synthase kinase 3β at ser9; hMSCs, human mesenchymal stem cells; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; OIM, osteogenic induction medium.